Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRYSALIS zorevunersen study in infants and toddlers with Dravet syndrome
jRCT2041260159Not yet recruiting
- Sponsor
- Stoke Therapeutics
- Start
- Nov 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Open-label trial of zorevunersen in Dravet syndrome (4 cohorts), sponsored by Stoke Therapeutics. Primary endpoints: Safety and tolerability of zorevunersen and Pharmacokinetic exposure of zorevunersen. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on jRCT2041260159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260159.